ACAD — Acadia Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $2.46bn
- $1.70bn
- $957.80m
- 73
- 54
- 60
- 66
Annual cashflow statement for Acadia Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -282 | -168 | -216 | -61.3 | 226 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 131 | 63.7 | 61.9 | 54.3 | -88.8 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 11 | -24.8 | 38 | 18.1 | 4.16 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -136 | -126 | -114 | 16.7 | 158 |
| Capital Expenditures | -7.59 | -1.12 | 0 | -40 | -0.523 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 200 | -70 | 73.2 | 72 | -30 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | 193 | -71.1 | 73.2 | 32 | -30.5 |
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 81 | 18.2 | 8.2 | 25.1 | 6.84 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 137 | -179 | -32.6 | 73.8 | 134 |